The Cu-Safe 300 is one of the latest additions to the array of available IUDs. It was specifically designed to decrease unwanted side-effects (e.g. bleeding, pain and expulsion) while providing simplicity of insertion, ease of removal and fair contraceptive protection. For comparison, the TCu380A was chosen. Both types were inserted at random in 600 recipients by a group of independent physicians with a long standing experience in intrauterine contraception. Life table analysis was used for comparison over a period of three years. The Cu-Safe 300 produced a slightly but not statistically significant higher pregnancy rate and more expulsions. Removals for bleeding and pain, however, were significantly less frequent. All inserting physicians agreed that insertion and removal of this new device was remarkably easy.

This paper reports the joint experience of three investigators who used three types of the Multiload (ML) IUD (MLCu250 Short, MLCu250 Standard, and MLCu375) in 1987 consecutive insertions during which an experience of 56,005 woman-months of use was accumulated. The material was analyzed using the life-table method and complemented with a case by case investigation, the main purpose of the study being the specific analysis of IUD-related complications. The authors also evaluated return of fertility whenever a device was removed because of wish of pregnancy. Results indicate that serious IUD-related complications were rare, continuation rate high, and reversibility of fertility unaffected by the device.

The efficacy and cycle control of and tolerance to a new oral contraceptive combination containing 0.150 mg desogestrel + 0.020 mg ethinylestradiol was investigated by seven Belgian investigators in a total of 295 women (7257 cycles). The trial was set up as a part of a larger European open multicenter study. This very low estrogen-dose combination was found to be a highly effective oral contraceptive preparation with a good cycle control. Only one pregnancy occurred (not a product failure). The frequency of absence of withdrawal bleeding was low (generally less than 6% during the initial treatment cycles, gradually decreasing to less than 3% after 20 cycles) and in most women the amount and duration of withdrawal bleeding showed no change or a slight decrease in comparison with those of the menstrual bleeding before treatment. The incidence of irregular bleeding (spotting and breakthrough bleeding) rapidly decreased over the subsequent treatment cycles, from 11.7% after 3 cycles to 8.8% after 6 cycles and less than 5% after 12 or more cycles. The preparation was well tolerated. There were no serious side effects and only 8 (2.7%) women dropped out because of minor side effects. ~ 44 78 75 49 26 23 295 15 26 25 17 9 8 100 Acta Obstet Gynecol Scand Suppl144 1984;10:42 -7. 4359 -66. 9. Bergink EW, van Meel F, Tbrpijn EW, van der Vies J. Binding of progestogens to receptor proteins in MCF-7 cells. J Steroid Biochem 1983;19:1563 -70. Acta Obstet Gynecor Scand Supp1144 Belgian trial of desogestrel-ethinylestradiol contraceptive 17 10. Bound W, Vessey M, Wiggins P. A randomized doubleblind trial of two low dose combined oral contraceptives. Br J Obstet Gynaecol 1979;86325 -9. Be 1 g i u m Acta Obstet Gynecol Scand Suppl144

No abstract

No abstract